Regencell Bioscience Holdings Limited

RGC

$6.48

+2.69%

N/A+$0.17

Healthcare

Drug Manufacturers - Specialty & Generic

NASDAQ

Active Trading

Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, ...

Supply Chain of RGC

Upstream

Foundry, packaging, memory, wafers, components, and input vendors.

Upstream

Sik-Kee Au (TCM Practitioner)

Hong Kong TCM Raw Material Wholesalers (Fragmented Market of 6,000+ Stores)

Regencell Bioscience Limited (Wholly-Owned HK Subsidiary)

Hong Kong Chinese Medicine Regulatory Office (CMRO)

Sik-Kee Au (TCM Practitioner)

Proprietary TCM formula provider and R&D partner. Holds exclusive license rights to the 'Sik-Kee Au TCM Brain Theory' formulae used in Regencell's product candidates. Party to a partnership agreement with Regencell since January 2018. Father of CEO Yat-Gai Au.

Hong Kong TCM Raw Material Wholesalers (Fragmented Market of 6,000+ Stores)

Supply of raw TCM herbal materials (e.g., Huangqi/Astragali Radix, Taoren/Persicae Semen) sourced under Hong Kong Chinese Medicine Regulatory Office guidelines. Materials are readily available from over 6,000 TCM stores and wholesalers in Hong Kong.

Regencell Bioscience Limited (Wholly-Owned HK Subsidiary)

Hong Kong operating subsidiary incorporated May 12, 2015, through which all TCM research, raw material procurement, and operations are conducted. 100% owned by the parent company.

Hong Kong Chinese Medicine Regulatory Office (CMRO)

Regulatory body governing the sourcing, quality, and safety of TCM raw materials in Hong Kong. All raw materials sourced under CMRO guidelines.

Downstream

Customers, distributors, OEMs, and channels that absorb output.

Downstream

Honor Epic Enterprises Limited

No current revenue-generating customers — pre-commercialization stage

Honor Epic Enterprises Limited

Joint venture partner (Regencell owns 60%, Honor Epic 40%) for development and commercialization of COVID-19 TCM treatment in ASEAN countries, India, Japan, Australia, and New Zealand. Honor Epic is responsible for 40% of JV capital and marketing/distribution efforts.

No current revenue-generating customers — pre-commercialization stage

The company has zero revenue, no approved products, and no identified commercial customers. Target patient populations are children/adults with mild, moderate, and severe ADHD and ASD in Hong Kong initially, with planned expansion to broader markets.

Geographic

Region-level exposures that can distort the supply network.

Geographic

Hong Kong / China

ASEAN / India / Japan / Australia / New Zealand

United States

Hong Kong TCM Raw Material Wholesalers (6,000+ stores)

Hong Kong Chinese Medicine Regulatory Office

Honor Epic Enterprises Limited

proxies

metadata

Hong Kong / China

Operational and regulatory dependency on Hong Kong's TCM regulatory framework. All R&D, raw material sourcing, and operations conducted in Hong Kong. Subject to Hong Kong Chinese Medicine Regulatory Office guidelines and potential changes in TCM regulation.

Hong Kong TCM Raw Material Wholesalers (6,000+ stores)Sole sourcing channel for all raw herbal materials

Hong Kong Chinese Medicine Regulatory OfficeRegulatory body governing TCM raw material quality and sourcing

Honor Epic Enterprises LimitedHong Kong-based JV partner for ASEAN COVID treatment distribution

ASEAN / India / Japan / Australia / New Zealand

Intended target markets for COVID-19 TCM treatment via Honor Epic JV. No revenue generated yet; depends on regulatory approvals in each jurisdiction.

Honor Epic Enterprises LimitedJV partner responsible for marketing and distribution in these regions

United States

NASDAQ-listed entity subject to SEC reporting requirements, US securities laws, and class action litigation risk. Multiple securities class action lawsuits filed in 2025-2026.

proxies

metadata

Concentration

Customer, supplier, or partner concentration exposures that can distort the supply network.

Foundry

Critical

Single-person dependency: 100% of the company's TCM formulae are provided by Sik-Kee Au (CEO's father) under a partnership agreement. Loss of this relationship would eliminate the company's sole product pipeline.

Other

Critical

CEO ownership concentration: Yat-Gai Au beneficially owns approximately 81-100% of outstanding ordinary shares, giving him absolute control over all corporate actions including board composition, M&A, and capital allocation.

Other

Critical

Zero revenue dependency on future unknowns: Company has never generated revenue and has no approved products. Entire business model depends on future regulatory approvals and successful commercialization, which may never occur.

Other

High

Single geography sourcing: All TCM raw materials sourced exclusively from Hong Kong TCM wholesalers. Any disruption to Hong Kong's TCM supply chain or regulatory environment would halt all R&D activity.

Revenue mix

How the target's revenue mix translates into supply-chain leverage and dependency.

TCM Formulae for ADHD/ASD (R&D stage)

0.0%

$0.0B

No commercial production yet; all upstream activity limited to R&D-scale sourcing of raw TCM herbs from Hong Kong wholesalers. No contract manufacturing scaled.

COVID-19 TCM Treatment (JV with Honor Epic)

0.0%

$0.0B

Joint venture established in 2021 with Honor Epic Enterprises for ASEAN/India/Japan/Australia/NZ markets; no revenue generated as of 2025.

Other TCM Research

0.0%

$0.0B

Pre-clinical research stage; no material supply chain activity.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer